Sugi Predict

Sugi Predict / Compounds / SCHEMBL4763328

SCHEMBL4763328

SCHEMBL4763328

CCN1CCC(c2ccc([N+](=O)[O-])cc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ SLC18A3 Q16572 1/20 0.55
▸ ALDH1A1 P00352 3/20 0.54
▸ HPGD P15428 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ POLB P06746 1/20 0.49
▸ TRPV6 Q9H1D0 1/20 0.48
▸ DRD2 P14416 2/20 0.46
▸ ESRRG P62508 1/20 0.45
▸ SIGMAR1 Q99720 2/20 0.45
▸ KCNJ1 P48048 1/20 0.44
▸ KCNH2 Q12809 1/20 0.44
▸ ACHE P22303 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2143870 0.84 SIGMAR1 (0.62) SLC18A3ALDH1A1KMT2ATRPV6ESRRG
SCHEMBL15561638 0.84 SLC18A3 (0.54) SLC18A3ALDH1A1TRPV6DRD2ESRRG
SCHEMBL1546066 0.84 DRD2 (0.54) SLC18A3ALDH1A1DRD2
SCHEMBL1546068 0.84 DRD2 (0.54) SLC18A3ALDH1A1DRD2
SCHEMBL426360 0.82 SLC18A3 (0.58) SLC18A3ALDH1A1HPGDKMT2APOLB
SCHEMBL1284674 0.82 SLC18A3 (0.60) SLC18A3ALDH1A1TRPV6DRD2ESRRG
SCHEMBL1284446 0.82 SLC18A3 (0.52) SLC18A3ALDH1A1TRPV6DRD2ESRRG
SCHEMBL21526604 0.81 SIGMAR1 (0.53) SLC18A3ALDH1A1TRPV6DRD2SIGMAR1
SCHEMBL1475645 0.81 SLC18A3 (0.51) SLC18A3ALDH1A1TRPV6ESRRGSIGMAR1
SCHEMBL17630267 0.81 SLC18A3 (0.51) SLC18A3POLBTRPV6ESRRGSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630530-B2 FGFR inhibitor compound and use thereof HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2026-05-19 — — US disclosed
EP-4186894-B1 FGFR INHIBITOR COMPOUND AND USE THEREOF HENAN MEDINNO PHARMACEUTICAL TECH CO LTD (CN) 2024-12-04 — — EP disclosed
US-20230192656-A1 FGFR INHIBITOR COMPOUND AND USE THEREOF HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-06-22 — — US disclosed
US-20230192656-A1 FGFR INHIBITOR COMPOUND AND USE THEREOF HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-06-22 — — US disclosed
EP-4186894-A1 FGFR INHIBITOR COMPOUND AND USE THEREOF Henan Medinno Pharmaceutical Technology Co., Ltd. (CN) 2023-05-31 — — EP disclosed
CN-113666911-A FGFR inhibitor compounds and uses thereof 河南迈英诺医药科技有限公司 2021-11-19 — — CN disclosed
US-20200079754-A1 INHIBITORS OF BRUTONS TYROSINE KINASE PHARMACYCLICS LLC (US) 2020-03-12 — — US disclosed
US-20190100505-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC (US) 2019-04-04 — — US disclosed
US-20180030027-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC (US) 2018-02-01 — — US disclosed
US-20180030027-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC (US) 2018-02-01 — — US disclosed
US-20150158865-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC 2015-06-11 — — US disclosed
US-20150158865-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC 2015-06-11 — — US disclosed
US-20150158865-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC 2015-06-11 — — US disclosed
US-8759517-B2 Pyrirnidinyl aryl urea derivatives being FGF inhibitors NOVARTIS AG (CH) 2014-06-24 — — US disclosed
US-20130030171-A1 Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors NOVARTIS AG (CH) 2013-01-31 — — US disclosed
US-8293746-B2 Pyrimidinyl aryl urea derivatives being FGF inhibitors NOVARTIS AG (CH) 2012-10-23 — — US disclosed
CN-101336237-A Pyrimidinyl aryl urea derivatives being fgf inhibitors NOVARTIS AG (CH) 2008-12-31 — — CN disclosed
US-20080312248-A1 Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors NOVARTIS AG 2008-12-18 — — US disclosed
EP-1976847-A2 PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS Novartis AG (CH) 2008-10-08 — — EP disclosed
WO-2007071752-A2 PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS NOVARTIS AG (CH) 2007-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630530-B2 FGFR inhibitor compound and use thereof FGFR3, FGFR1, FGFR4 SLC18A3 3727/4885ALDH1A1 1323/4885HPGD 4078/4885
US-20080312248-A1 Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors FGFR1, FGF1, FGF2 SLC18A3 4758/4885ALDH1A1 910/4885HPGD 677/4885
US-20230192656-A1 FGFR INHIBITOR COMPOUND AND USE THEREOF FGFR3, FGFR1, FGFR4 SLC18A3 2894/4885ALDH1A1 1320/4885HPGD 2869/4885
US-20180030027-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE BTK, LYN, LCK SLC18A3 4832/4885ALDH1A1 4745/4885HPGD 4062/4885
US-20200079754-A1 INHIBITORS OF BRUTONS TYROSINE KINASE BTK, LYN, LCK SLC18A3 4791/4885ALDH1A1 4726/4885HPGD 3959/4885
US-20190100505-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE BTK, LYN, LCK SLC18A3 4824/4885ALDH1A1 4737/4885HPGD 4059/4885
US-20130030171-A1 Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors FGFR1, FGF1, FGF2 SLC18A3 4758/4885ALDH1A1 910/4885HPGD 677/4885
US-20150158865-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE BTK, LYN, LCK SLC18A3 4824/4885ALDH1A1 4737/4885HPGD 4059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.